Cocaine and Polydrug Abuse: New Medication Strategies

这是NIDA计划项目（P-01）的新申请，标题为可卡因和多种药物滥用：新的药物治疗策略。可卡因滥用仍然是该国最严重的药物滥用问题之一，迄今为止，还没有有效的抗可卡因药物。可卡因经常与海洛因一起滥用，对可卡因和类阿片的双重依赖使药物治疗进一步复杂化。提出了四个相互关联的临床和临床前研究项目，以开发治疗可卡因滥用和多种药物滥用的新药。这些多学科合作项目涉及行为科学，内分泌学，神经生物学和药理学。一个创新的新的Speedball（可卡因+海洛因）滥用的临床前模型将用于评估新的药物策略，并测试假设，即针对可卡因和Speedball的阿片类成分的药物组合将比单独使用抗可卡因或抗阿片类药物更有效。将评价潜在抗可卡因药物（内分泌调节剂、多巴胺再摄取抑制剂;多巴胺激动剂和拮抗剂）和抗阿片类药物（高和中效mu激动剂和新型长效mu拮抗剂）的急性和慢性治疗。除了药理学方法，我们建议评估新的生物学方法，以减少可卡因滥用的基础上，我们最近发现的可卡因神经内分泌相互作用。我们假设可卡因的急性神经内分泌效应可能导致其滥用相关效应，可卡因-内分泌相互作用的分析将指导药物开发的新策略。将在临床和临床前研究中检查可卡因刺激垂体前叶、性腺和肾上腺激素之间的时间协方差。可卡因的急性内分泌效应的行为相关性将在可卡因滥用治疗的生物学方法的临床研究和临床前研究中进行评估。可卡因急性内分泌效应的药理学机制将在临床前研究中用选择性单胺激动剂和拮抗剂进行评价。此外，我们建议系统地检查可卡因急性内分泌特征的变化，这些变化是由（a）在狂欢模式中重复给予可卡因，（B）将海洛因添加到可卡因中以模拟可卡因滥用治疗药物疗效的环境所产生的。这些研究应澄清可卡因滥用影响神经内分泌因素和受神经内分泌因素影响的方式。在了解药物滥用相关影响的神经生物学决定因素方面取得的进展应有助于开发更有效的治疗药物。

This is a new application for a NIDA Program Project (P-01) entitled Cocaine and Polydrug Abuse: New Medication Strategies. Cocaine abuse remains one of the nation's most serious drug abuse problems, and as yet, there are no effective anti-cocaine medications. Cocaine is often abused in combination with heroin, and dual dependence on cocaine and opioids further complicates medication based treatment. Four inter- related clinical and pre-clinical research projects are proposed to develop novel medications for the treatment of cocaine abuse and polydrug abuse. These multi-disciplinary collaborative projects involve behavioral science, endocrinology, neurobiology and pharmacology. An innovative new preclinical model of speedball (cocaine+heroin) abuse will be used to evaluate novel medication strategies, and to test the hypothesis that medication combinations targeted at both the cocaine and the opioid components of the speedball will be more effective than treatment with either anti-cocaine or anti-opioid medications alone. Acute and chronic treatment with potential anti-cocaine medications (endocrine modulators, dopamine reuptake inhibitors; dopamine agonists and antagonists ) and anti-opioid medications (high and intermediate efficacy mu agonists and a new long-acting mu antagonist) will be evaluated. In addition to pharmacological approaches, we propose to evaluate novel biologic approaches to reduce cocaine abuse that are based on our recent discoveries of cocaine-neuroendocrine interactions. We hypothesize that the acute neuroendocrine effects of cocaine may contribute to its abuse- related effects and that analysis of cocaine-endocrine interactions will guide new strategies for medications development. The temporal covariance between cocaine stimulation of anterior pituitary, gonadal and adrenal hormones will be examined in both clinical and preclinical studies. The behavioral relevance of cocaine's acute endocrine effects will be evaluated both in clinical studies and preclinical studies of biologic approaches to cocaine abuse treatment. The pharmacological mechanisms underlying cocaine's acute endocrine effects will be evaluated with selective monoamine agonists and antagonists in preclinical studies. In addition, we propose to systematically examine changes in the acute endocrine profile of cocaine produced by (a) repeated cocaine dosing in a binge pattern, (b) the addition of heroin to cocaine to simulate milieu on the efficacy of medications for cocaine abuse treatment will e examined. These studies should clarify the ways in which cocaine abuse influences and is influenced by neuroendocrine factors. Advances in understanding the neurobiological determinants of the abuse-related effects of drugs should facilitate the development of more effective treatment medications.